Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
Business Wire•22/10/2026•08:00 ET
0
Key Highlights
- ➤Gilead will present 21 abstracts at The Liver Meeting 2026.
- ➤Late-breaking IDEAL Phase 3 data assess Livdelzi’s composite ALP normalization in PBC.
- ➤Seladelpar safety and efficacy data extend through five years of treatment.
- ➤Hepcludex data include 96-week combined virologic and biochemical response findings.
- ➤Real-world studies highlight low HDV testing rates and advanced liver disease burden.
Expert Statements
Swati Tole, Senior Vice President, Clinical Development, Inflammation at Gilead
“As treatment options evolve, our ambitions for people living with rare liver diseases should evolve as well,”
Swati Tole, Senior Vice President, Clinical Development, Inflammation at Gilead
“At The Liver Meeting, we will present late-breaking results from the Phase 3 IDEAL study highlighting composite alkaline phosphatase (ALP) normalization, an important marker of disease activity in people with PBC.”
Swati Tole, Senior Vice President, Clinical Development, Inflammation at Gilead
“We will also share data that look beyond biochemical measures of disease activity to explore durability of response, symptoms and the realities of long-term disease management.”
Swati Tole, Senior Vice President, Clinical Development, Inflammation at Gilead
“Together, these insights can help broaden our understanding of important aspects of care for people living with PBC.”
Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting(®) 2026
- Late-Breaking Phase 3 Data from the IDEAL Study Highlight the Impact of Livdelzi(®) on Composite Alkaline Phosphatase (ALP) Normalization and Other Markers of Disease Progression in Primary Biliary Cholangitis (PBC) -
Get started
Create a free account to read the full story.